23 completed, 4 active not recruiting, 3 recruiting. 20 Phase 1, 8 Phase 3, 3 Phase 2.
By phase and status
Follow MK-0616: new trials by email Literature Review of MK-0616 trials Research Report on MK-0616
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) Enlicitide Decanoate, Placebo - Hyperlipidemia, Hypercholesterolemia Phase 3 Recruiting 150 2026-10-15 2026-11-02 A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044) Enlicitide - Healthy Phase 1 Active not recruiting 30 2026-08-31 2026-09-18 A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003) MK-7262, Enlicitide - Healthy Phase 1 Completed 30 2026-07-01 2026-09-25 A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) MK-7262, Enlicitide, Placebo for MK-7262 - Lipoprotein(a) Phase 2 Recruiting 750 2026-06-30 2026-10-23 A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041) Enlicitide - Healthy Phase 1 Completed 30 2026-03-23 2026-06-02 A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039) MK-0616A, Enlicitide, Rosuvastatin - Healthy Phase 1 Completed 60 2025-12-29 2026-11-06 A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) Enlicitide, Rosuvastatin, Placebo for Enlicitide - Hyperlipidemia Phase 3 Active not recruiting 996 2025-11-11 2026-09-01 A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) Enlicitide Decanoate, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) Phase 2 / Phase 3 Recruiting 153 2025-08-21 2026-11-10 A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040) Enlicitide - Healthy Phase 1 Completed 60 2025-07-03 2025-09-03 A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035) Enlicitide - Healthy Phase 1 Completed 40 2025-04-02 2025-06-15 A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032) Enlicitide - Healthy, Renal Impairment Phase 1 Completed 27 2024-11-22 2026-10-20 A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033) Enlicitide - Healthy Phase 1 Completed 20 2024-10-21 2025-02-07 Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension Enlicitide Decanoate - Hypercholesterolemia Phase 3 Active not recruiting 3000 2024-08-05 2025-10-07 A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) Enlicitide, Ezetimibe, Bempedoic Acid - Hypercholesterolemia Phase 3 Completed 301 2024-07-08 2026-03-27 A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028) Levothyroxine, Enlicitide Decanoate - Healthy Phase 1 Completed 28 2024-07-08 2024-10-03 A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027) Alendronate, Enlicitide Decanoate - Healthy Phase 1 Completed 36 2024-04-23 2025-02-18 A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026) Warfarin, Enlicitide Decanoate, Lisinopril - Healthy Phase 1 Completed 36 2024-04-01 2025-01-15 A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025) Enlicitide decanoate - Healthy Phase 1 Completed 40 2024-03-18 2024-11-18 A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) Enlicitide Decanoate, Semaglutide - Healthy Phase 1 Completed 38 2024-01-22 2024-11-21 The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022) Enlicitide decanoate - Healthy Phase 1 Completed 34 2023-10-24 2024-10-26
Showing 20 of 30. Sign in to see all of them.
Conditions studied Hypercholesterolemia (10) · Hyperlipoproteinemia Type II (3) · Hyperlipidemias (2) · Arteriosclerosis (1) · Renal Insufficiency (1)
Sponsors Merck Sharp & Dohme LLC (30)
Countries United States (28) · Spain (8) · Canada (6) · Colombia (6) · Germany (6) · Israel (6) · Japan (6) · United Kingdom (6) · Argentina (5) · Australia (5) · Brazil (5) · China (5) · Mexico (5) · Netherlands (5) · New Zealand (5)
Results publications PMID 36889610 , PMID 41206969 , PMID 41879224 , PMID 42017875
NIH funding 2023 (2) , 2025 (2)